H
Henry Li
Publications - 11
Citations - 1148
Henry Li is an academic researcher. The author has contributed to research in topics: Hereditary angioedema & Angioedema. The author has an hindex of 8, co-authored 9 publications receiving 1036 citations.
Papers
More filters
Journal ArticleDOI
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
Tom Bowen,Marco Cicardi,Henriette Farkas,Konrad Bork,Hilary Longhurst,Bruce L. Zuraw,Emel Aygoeren‐Pürsün,Timothy J. Craig,Karen Binkley,Jacques Hébert,Bruce Ritchie,Laurence Bouillet,Stephen Betschel,Della Cogar,John M. Dean,Ramachand Devaraj,Azza Hamed,Palinder Kamra,Paul K. Keith,Gina Lacuesta,Eric Leith,Harriet Lyons,Sean R. Mace,Barbara Mako,Doris Neurath,Man-Chiu Poon,Georges-Etienne Rivard,R. Robert Schellenberg,Dereth Rowan,Anne Rowe,Donald Stark,Smeeksha Sur,Ellie Tsai,Richard Warrington,Susan Waserman,Rohan Ameratunga,Jonathan A. Bernstein,Janne Björkander,Kristylea Brosz,John Brosz,Anette Bygum,Teresa Caballero,Michael M. Frank,George Füst,George Harmat,Amin Kanani,Wolfhart Kreuz,Marcel Levi,Henry Li,Inmaculada Martinez-Saguer,Dumitru Moldovan,István Nagy,Erik Waage Nielsen,Patrik Nordenfelt,Avner Reshef,E. Rusicke,Sarah Smith-Foltz,Peter J. Späth,Lilian Varga,Zhi Yu Xiang +59 more
TL;DR: Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches.
Journal ArticleDOI
Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema
Tom Bowen,Marco Cicardi,Konrad Bork,Bruce L. Zuraw,Michael M. Frank,Bruce Ritchie,Henriette Farkas,Lilian Varga,Lorenza C. Zingale,Karen Binkley,Eric Wagner,Peggy Adomaitis,Kristylea Brosz,Jeanne Burnham,Richard Warrington,Chrystyna Kalicinsky,Sean R. Mace,Christine McCusker,R. Robert Schellenberg,Lucia Celeste,Jacques Hébert,Karen A. Valentine,Man-Chiu Poon,Bazir Serushago,Doris Neurath,William H. Yang,Gina Lacuesta,Andrew C. Issekutz,Azza Hamed,Palinder Kamra,John M. Dean,Amin Kanani,Donald Stark,Georges-Etienne Rivard,Eric Leith,Ellie Tsai,Susan Waserman,Paul K. Keith,David Page,Silvia Marchesin,Hilary Longhurst,Wolfhart Kreuz,E. Rusicke,Inmaculada Martinez-Saguer,Emel Aygören-Pürsün,George Harmat,George Füst,Henry Li,Laurence Bouillet,Teresa Caballero,Dumitru Moldovan,Peter J. Späth,Sara Smith-Foltz,István Nagy,Erik Waage Nielsen,Christoph Bucher,Patrik Nordenfelt,Zhi Yu Xiang +57 more
TL;DR: There is a paucity of double-blind, placebo-controlled trials on the treatment of HAE, making levels of evidence to support the algorithm less than optimal.
Journal ArticleDOI
Current state of hereditary angioedema management: a patient survey.
Aleena Banerji,Paula J. Busse,Sandra C. Christiansen,Sandra C. Christiansen,Henry Li,William R. Lumry,Mark Davis-Lorton,Jonathan A. Bernstein,Michael M. Frank,Anthony J. Castaldo,Janet Long,Bruce L. Zuraw,Bruce L. Zuraw,Marc A. Riedl,Marc A. Riedl +14 more
TL;DR: The findings show that HAE management is improving with good access to on-demand and prophylactic treatment options, however, HAE patients still have a significant burden of disease and continued research and educational efforts are needed.
Journal ArticleDOI
Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial
Marc A. Riedl,Jonathan A. Bernstein,Henry Li,Avner Reshef,William R. Lumry,Dumitru Moldovan,Henriette Farkas,Robyn J. Levy,James R. Baker,Yun Hardiman,Mark C. Totoritis,Anurag Relan,Marco Cicardi +12 more
TL;DR: Overall, rhC1INH was safe and well tolerated; no thromboembolic events, anaphylaxis, or neutralizing antibodies were observed and results are consistent with previous studies showing efficacy and safety of rhC 1INH in patients with HAE.
Journal ArticleDOI
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
Timothy J. Craig,Bruce L. Zuraw,Hilary Longhurst,Marco Cicardi,Konrad Bork,Clive Grattan,Constance H. Katelaris,Gordon Sussman,Paul K. Keith,William H. Yang,Jacques Hébert,Jana Hanzlikova,Petra Staubach-Renz,Inmaculada Martinez-Saguer,Markus Magerl,Emel Aygören-Pürsün,Henriette Farkas,Avner Reshef,Shmuel Kivity,Sergio Neri,Ioana Crisan,Teresa Caballero,Maria L. Baeza,Maria Dolores Hernandez,Henry Li,William R. Lumry,Jonathan A. Bernstein,Iftikar Hussain,John Anderson,Lawrence B. Schwartz,Joshua J. Jacobs,Michael E. Manning,Donald Levy,Marc A. Riedl,Sandra C. Christiansen,Henrike Feuersenger,Ingo Pragst,Sarah Mycroft,Dipti Pawaskar,Iris Jacobs +39 more
TL;DR: In patients with frequent HAE attacks, long-term replacement therapy with C1-INH(SC) is safe and exhibits a substantial and sustained prophylactic effect, with the vast majority of patients becoming free from debilitating disease symptoms.